New approach in prophylactic treatment of a challenged HAE patient

BMJ Case Rep. 2019 Mar 4;12(3):e227061. doi: 10.1136/bcr-2018-227061.

Abstract

Hereditary angioedema (HAE) is a relapsing swelling disorder which can cause severe pain, affect quality of life and potentially be life threatening with involvement of the airways. We present a 34-year-old immigrant who suffered from very frequent and severe HAE attacks. The attacks often involved the face, mouth and the airways. She often went to the hospital for treatment, where the language barrier made the situation complicated. The traditional therapy for HAE was not successful treating this patient. In June 2017, off-label treatment with prophylactic subcutaneous complement C1-inhibitor concentrate was initiated. The treatment was very successful and the patient has not been hospitalised since. Treatment for HAE is nowadays under investigation, and many drugs are under development. Especially, medication which works prophylactically and is administered orally or subcutaneously is in the horizon.

Keywords: dermatology; genetics; immunology; medical management.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angioedemas, Hereditary / drug therapy*
  • Angioedemas, Hereditary / physiopathology
  • Complement C1 Inhibitor Protein / pharmacology
  • Complement C1 Inhibitor Protein / therapeutic use*
  • Complement Inactivating Agents / pharmacology
  • Complement Inactivating Agents / therapeutic use*
  • Female
  • Humans
  • Off-Label Use
  • Patient Education as Topic
  • Quality of Life
  • Self Administration
  • Treatment Outcome

Substances

  • Complement C1 Inhibitor Protein
  • Complement Inactivating Agents